Curr Opin Allergy Clin Immunol August 2019 PMID 31169593

Second generation antihistamines: an update.

Mario Sánchez-Borges, Ignacio J Ansotegui

Full text PDF Download social card

Mentions

Peak: 2 in Jun 2019

across 2 sources since Jun 2019

Extended reach

7,839

potential audience

Total likes

Video views

5,913

Mentions per month

Jun 2019 – Dec 2024

Where it's discussed

X / Twitter4 posts
YouTube3 videos

AI synopsis

What people are saying

Several posts, such as references to the effectiveness and safety of second-generation antihistamines and their status as first-line treatments, demonstrate significant interest and agreement. The tone is informative and proactive, with phrases like 'update' and 'role in allergic disease' indicating an appreciation for new insights, which underscores their potential impact on clinical approaches.

AgreementModerate agreement

Most discussions recognize the value and safety of second-generation antihistamines as a recommended treatment, with some explicitly supporting the updated guidelines.

InterestHigh interest

Participants are highly interested, displaying enthusiasm for recent research developments and potential clinical applications.

EngagementModerate engagement

The posts show a moderate level of engagement, with some referencing specific studies, mechanisms, and clinical implications.

ImpactModerate impact

The discussions suggest the publication could influence clinical practice by reinforcing the safety and efficacy of these antihistamines.

Abstract in brief

The article provides an update on the pharmacology, mechanisms, and safety of second-generation antihistamines (SGAHs).
Recent studies support the effectiveness and safety of SGAHs, making them the preferred first-line treatment for allergic rhinoconjunctivitis and urticaria.
The review aims to help healthcare providers properly use SGAHs to treat these common allergic conditions.]

Read the full abstract